Our Business
Our Company was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited We are a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products – parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal (“ABFS”) and Injection Strech Blow Moulding (“ISBM”) technology.
We manufacture large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) in six therapeutic segments.
Our product Portfolio can be categorized into the following six Therapeutic Segments.
- Fluid therapy – (IV Fluid)
- Formulations
- Diluents and Injectables
- Ophthalmic
- Respiratory care and
- Irrigation solutions in therapeutic segment
We are a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products – parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal (“ABFS”) and Injection Strech Blow Moulding (“ISBM”) technology.
We manufacture large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) in six therapeutic segments.
In addition to that, we also manufacturer medical devices.
We manufacture fluid therapy – (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants in medical device segment .
We offer wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2ml to 1000 ml.
Our formulation and development operations help us to develop new formulation as well as modify / improve the formulation for our own brand as well as our customers for product partnering business.
We have a dedicated Formulation and Development (“F&D”) and quality control laboratory located at our manufacturing facility in Hariyala, District Kheda, Gujarat, India.
We have four LVPs manufacturing lines, which include two lines of conventional single port containers with ABFS technology and two lines for SteriPort products with ISBM technology. Similarly, we have three operational SVPs manufacturing lines, which includes two ABFS lines and one conventional three-piece container filling lines.
Our manufacturing facility has good manufacturing practices (“GMP”) certifications from the Food & Drugs Control Administration, Gujarat, in conformity with the format recommended by the World Health Organization (the “WHO”), the GMP for formulations from Cambodia, Sudan, Philippines, Zimbabwe. We also have certificate from DNV for exports of medical device products.
Our cGMP capabilities allow us to offer our customers various products of sterile liquid form in product categories of quinolones, anti-biotics, anti-fungal, diuretic, anti-anaerobic, Ophthalmic, Respiratory etc.
We market our products through three strategic business units namely (a) national sales, (b) international sales and (c) product partnering with various foreign and Indian pharmaceutical companies.
We manufacture diverse generics product portfolio of over 45 products and market them under our own brands in the Indian market througha network of over 316 distributors and stockists.
We sell our products in various countries including the Africa, Latin America, UK and the Rest of the world. Our Company’s products are currently registered with 19 countries and have a compliance track record with a range of regulatory regimes across these markets.
During the Fiscal 2024, we exported branded products to 19 countries. In product partnering, our Company undertakes
manufacturing for various pharmaceutical companies.
Our international sales business covers, advanced market countries and emerging market countries.
As on the date of this Draft Red Herring Prospectus, we have a portfolio of 47 products registered across 112 international jurisdictions.
Our product partnering business include commercial large-scale manufacturing of generic products.
We also undertake manufacturing under loan license agreements with our customers. Under product partnering model, we have developed relationships across the Indian pharmaceutical industry and some of our key customers.
We have sales, marketing and distribution capabilities in India. We have over 316 distributors/stockist’ network supported by sales team of approximately 108 people.
We primarily sell our products to distributors in India, who in turn supplies to Hospital and Nursing Homes, etc.
We have focused our international branded generic product business on emerging and semi-regulated international markets but are expanding our business to regulated markets like the UK and Zimbabwe, Sudan, Cambodia, Philippines and Ethiopia.
OBJECTS OF THE OFFER
- Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.
- Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat.
- General corporate purposes.
Qualitative Factors
- Well established manufacturer of pharmaceutical formulations with diverse product portfolio and diverse market.
- Large manufacturing capabilities.
- Wide Domestic and International Marketing Network.
- Experienced management team supported by large, diverse and skilled work force.
Comparison of accounting ratios with listed industry peers
- Amanta Healthcare Limited.
- Denis Chem Lab Limited.
